Loading...
Docoh

La Jolla Pharmaceutical (LJPC)

Utility
Methods for treating hypotension in a patient that has received an ACE inhibitor by administering angiotensin II
11 Jan 22
The present disclosure relates to the use of angiotensin II, angiotensin III, or angiotensin IV in therapeutic methods for the treatment of hypotension, especially catecholamine-resistant hypotension.
George Tidmarsh, Lakhmir Chawla
Filed: 4 Mar 21
Utility
Methods for Administering Angiotensin II
24 Jun 21
The present disclosure relates to the use of angiotensin II, angiotensin III, or angiotensin IV in therapeutic methods for the treatment of hypotension, especially catecholamine-resistant hypotension.
George Tidmarsh, Lakhmir Chawla
Filed: 4 Mar 21
Utility
Methods of Administering Hepcidin
6 May 21
The present disclosure relates to the use of hepcidin in therapeutic methods for the treatment of various conditions in which decreasing serum iron concentration may be beneficial.
Lakhmir Chawla, George Tidmarsh
Filed: 19 Dec 17
Utility
Methods for Administering Angiotensin II
4 Feb 21
The present disclosure relates to the use of angiotensin II, angiotensin III, or angiotensin IV in therapeutic methods for the treatment of hypotension, especially catecholamine-resistant hypotension.
George Tidmarsh, Lakhmir Chawla
Filed: 26 Mar 20
Utility
Methods for Treating Hypotension
29 Jul 20
The present disclosure relates to the use of angiotensin II in therapeutic methods for the treatment of hypotension, especially catecholamine-resistant hypotension.
George Tidmarsh, Lakhmir Chawla
Filed: 16 Apr 20
Utility
Methods for Administering Angiotensin II
15 Jul 20
The present disclosure relates to the use of angiotensin II, angiotensin III, or angiotensin IV in therapeutic methods for the treatment of hypotension, especially catecholamine-resistant hypotension.
Lakhmir Chawla, George Tidmarsh, Steve Ching Tsung Chen
Filed: 12 Apr 18
Utility
Glycolipids as treatment for disease
10 Feb 20
This invention provides compounds, compositions, and methods for treating a disorder selected from cancer, hyperinsulinemia, hypoglycemia, hyperinsulinemia with hypoglycemia, atypical Parkinson's disease, Huntington's disease, multiple systems atrophy, GM3 synthase deficiency, GM2 synthase deficiency or tauopathy.
Shawn Defrees
Filed: 22 Nov 15
Utility
Compositions and Methods for Treating Iron Overload
6 Nov 19
The present disclosure relates to the use of hepcidin, mini-hepcidin, or a hepcidin analogue in therapeutic methods for the treatment and/or prevention of acquired iron overload or other conditions for which iron redistribution or sequestration is helpful.
George Tidmarsh, Lakhmir Chawla
Filed: 17 Jan 18
Utility
Compositions Comprising Hepcidin and Methods of Use Thereof
16 Oct 19
Provided herein are improved compositions comprising hepcidin.
James Rolke, Harry Wang
Filed: 21 Feb 19
  • 1
Patents are sorted by USPTO publication date, most recent first